CTLA4 and cancer: Immune checkpoint inhibitors (ICI) are monoclonal antibodies that block these pathways by binding to PD-1/L1 or CTLA-4 and enhance the immune response against cancer cells [7] and have demonstrated ground-breaking results in several cancers [8].